Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

Código QR

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

Sarah Bassiony, Claire N Harrison, Donal P McLornan Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UKCorrespondence: Donal P McLornanDepartment of Haematology, Guy’s and St Thomas’ NHS Foundation Trust,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bassiony S, Harrison CN, McLornan DP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	myelofibrosis jak inhibitors momelotinib Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/6e55eacd587643f6a14e3b28f2c17888
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
por: A. N. Alekseeva, et al.
Publicado: (2017)

Disseminated tuberculosis with myelofibrosis presentation: a case report
por: Mahdi Khatuni, et al.
Publicado: (2021)

New Markers of Disease Progression in Myelofibrosis
por: Rita Campanelli, et al.
Publicado: (2021)

Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis
por: Ali M Gabali, et al.
Publicado: (2014)

Coexistence of Prefibrotic Myelofibrosis with Monoclonal Gammopathy of Undetermined Significance: A Case Report
por: Omar M. Ismail, et al.
Publicado: (2021)

VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis
por: Laura Villani, et al.
Publicado: (2021)

New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options
por: Domenico Penna
Publicado: (2021)

Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
por: Giulia Radi, et al.
Publicado: (2021)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Fei Qi, et al.
Publicado: (2021)

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti MS, et al.
Publicado: (2020)

Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
por: Lukas M. Braun, et al.
Publicado: (2021)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane C, et al.
Publicado: (2013)

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
por: Daniele Cattaneo, et al.
Publicado: (2021)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
por: Keohane C, et al.
Publicado: (2013)

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
por: Harrington R, et al.
Publicado: (2020)

Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients
por: Song Zhang, et al.
Publicado: (2021)

Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
por: Zhang N, et al.
Publicado: (2021)

Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients
por: Taheri M, et al.
Publicado: (2018)

Edaravone alleviates cell apoptosis and mitochondrial injury in ischemia-reperfusion-induced kidney injury via the JAK/STAT pathway
por: Zhao,Xiaoying, et al.
Publicado: (2020)

Tofacitinib Ameliorates Retinal Vascular Leakage in a Murine Model of Diabetic Retinopathy with Type 2 Diabetes
por: Eimear M. Byrne, et al.
Publicado: (2021)

Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
por: Giovanni Barosi, et al.
Publicado: (2012)

Recent developments in myelofibrosis
por: Mesa RA, et al.
Publicado: (2012)

Therapeutic effects of an innovative BS-HH-002 drug on pancreatic cancer cells via induction of complete MCL-1 degradation
por: A-min Wang, et al.
Publicado: (2022)

Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher H, et al.
Publicado: (2019)

Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date
por: Whitfield T, et al.
Publicado: (2016)

CXCL8(3-72) K11R/G31P protects against sepsis-induced acute kidney injury via NF-κB and JAK2/STAT3 pathway
por: Zhou,Yunfeng, et al.
Publicado: (2019)

Hepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats
por: Hafez,Mohamed M, et al.
Publicado: (2015)

Ruxolitinib as an emerging treatment in myelofibrosis
por: Emanuel RM, et al.
Publicado: (2013)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti F, et al.
Publicado: (2019)

INHIBITIVE EFFECT OF DATE EXTRACT ON THE CORROSION OF CARBON STEEL IN ACIDIC MEDIA
por: MOUSSAOUI,NAIMA, et al.
Publicado: (2016)

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients
por: Zhang N, et al.
Publicado: (2018)

Molecular basis of essential thrombocythaemia in humans and dogs – a review
por: Nicola Padzik, et al.
Publicado: (2021)

Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
por: YU Xuxu, et al.
Publicado: (2021)

Discovery of a novel potentially transforming somatic mutation in CSF2RB gene in breast cancer
por: Mamoon Rashid, et al.
Publicado: (2021)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
por: Jack W Singer, et al.
Publicado: (2019)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Yuliya Lytvyn, PhD, et al.
Publicado: (2022)

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis
por: Margaux Sevin, et al.
Publicado: (2018)

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
por: Hill L, et al.
Publicado: (2018)

JQ-1 ameliorates schistosomiasis liver fibrosis by suppressing JAK2 and STAT3 activation
por: Han Ding, et al.
Publicado: (2021)

AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1
por: Ruing Zhao, et al.
Publicado: (2021)